KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $324.0 million.

  • CRISPR Therapeutics AG's Total Non-Current Liabilities rose 359.76% to $324.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $324.0 million, marking a year-over-year increase of 359.76%. This contributed to the annual value of $306.5 million for FY2024, which is 1136.46% down from last year.
  • CRISPR Therapeutics AG's Total Non-Current Liabilities amounted to $324.0 million in Q3 2025, which was up 359.76% from $314.1 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Total Non-Current Liabilities peaked at $394.1 million during Q3 2022, and registered a low of $144.3 million during Q1 2021.
  • Its 5-year average for Total Non-Current Liabilities is $332.1 million, with a median of $345.8 million in 2023.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Total Non-Current Liabilities skyrocketed by 14531.38% in 2022 and then plummeted by 1158.26% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Total Non-Current Liabilities (Quarter) stood at $345.1 million in 2021, then increased by 4.79% to $361.6 million in 2022, then decreased by 4.37% to $345.8 million in 2023, then dropped by 11.36% to $306.5 million in 2024, then grew by 5.72% to $324.0 million in 2025.
  • Its last three reported values are $324.0 million in Q3 2025, $314.1 million for Q2 2025, and $333.6 million during Q1 2025.